GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Autobio Diagnostics Co Ltd (SHSE:603658) » Definitions » Debt-to-EBITDA

Autobio Diagnostics Co (SHSE:603658) Debt-to-EBITDA : 0.51 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Autobio Diagnostics Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Autobio Diagnostics Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥491 Mil. Autobio Diagnostics Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥264 Mil. Autobio Diagnostics Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ¥1,473 Mil. Autobio Diagnostics Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.51.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Autobio Diagnostics Co's Debt-to-EBITDA or its related term are showing as below:

SHSE:603658' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.06   Med: 0.16   Max: 0.71
Current: 0.51

During the past 13 years, the highest Debt-to-EBITDA Ratio of Autobio Diagnostics Co was 0.71. The lowest was 0.06. And the median was 0.16.

SHSE:603658's Debt-to-EBITDA is ranked better than
68.47% of 425 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs SHSE:603658: 0.51

Autobio Diagnostics Co Debt-to-EBITDA Historical Data

The historical data trend for Autobio Diagnostics Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autobio Diagnostics Co Debt-to-EBITDA Chart

Autobio Diagnostics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.19 0.16 0.08 0.39

Autobio Diagnostics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.42 0.43 0.50 0.51

Competitive Comparison of Autobio Diagnostics Co's Debt-to-EBITDA

For the Medical Devices subindustry, Autobio Diagnostics Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Autobio Diagnostics Co's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Autobio Diagnostics Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Autobio Diagnostics Co's Debt-to-EBITDA falls into.



Autobio Diagnostics Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Autobio Diagnostics Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(698.521 + 24.636) / 1838.693
=0.39

Autobio Diagnostics Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(491.335 + 263.667) / 1472.64
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Autobio Diagnostics Co  (SHSE:603658) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Autobio Diagnostics Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Autobio Diagnostics Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Autobio Diagnostics Co (SHSE:603658) Business Description

Traded in Other Exchanges
N/A
Address
No.199, 15th Avenue, National Economic and Technological Development Area, Zhengzhou, CHN, 450016
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, marketing and service of clinical diagnostic products, including immunoassay, microbiology and biochemical products. It focuses on the common development of both reagents and instruments. Reagents products include immunoassay, biochemistry, microbiology, and IVD subdivision areas, and instruments include both full automation and semi-automation instruments and systems. Geographically it holds a strong distribution network with thousands of distributors in the Chinese market.
Executives
Miao Yong Jun Director

Autobio Diagnostics Co (SHSE:603658) Headlines

No Headlines